Castle Biosciences Inc.

CSTL Nasdaq SEC CIK 1447362
Follow Castle Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $102.9M +23.9% vs same quarter last year
Net income −$4.1M −718.4% vs same quarter last year
EPS, diluted −$0.13 −550% vs same quarter last year
Operating cash flow $19.7M −12.8% vs same quarter last year
Revenue by quarter
$86.3M
$88M
$86.2M
$83M
$87M
$83.7M
$103.5M
$102.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$344.2M−$24.2M
FY24$332.1M$18.2M
FY23$219.8M−$57.5M
FY22$137M−$67.1M
FY21$94.1M−$31.3M
FY20$62.6M−$10.3M
FY19$51.9M-
FY18$22.8M−$6.4M
FY17--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−100%−50%0%50%100%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2579.4%−12.4%−7%
FY2481.9%2.6%5.5%
FY2379.5%−30.9%−26.1%
FY2276.6%−53.2%−49%
FY2183.2%−42.6%−33.3%
FY2084.5%−10.4%−16.4%
FY1985.9%14.1%-
FY1876.8%−16.8%−27.9%
FY17---
Free cash flowOperating cash flow minus capital expenditure
−$50M−$25M$0$25M$50MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$28.3M
FY24$36.5M
FY23−$19.2M
FY22−$47.3M
FY21−$22.5M
FY20$5.1M
FY19$6.1M
FY18−$12.6M
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Castle Biosciences
  • Healthcare median
−100%−75%−50%−25%0%25%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearCastle BiosciencesHealthcare median
FY25−7%−30.6%
FY245.5%−47%
FY23−26.1%−58%
FY22−49%−80.4%
FY21−33.3%−71.8%
FY20−16.4%−62.2%
FY19-−46.2%
FY18−27.9%−49.6%
FY17-−45.9%